Seattle, WA 的 T細胞淋巴瘤 臨床試驗
6 項針對 T細胞淋巴瘤 的研究正在 Seattle(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
招募中2 期
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
招募中3 期
- University of Washington Fred Hutch Cancer Center, Seattle
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
招募中3 期
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
招募中1/2 期
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
招募中1 期
- Seattle Children's Hospital, Seattle
其他城市的 T細胞淋巴瘤 試驗
- New York City, NY13 項研究
- Philadelphia, PA10 項研究
- Baldwin Park, CA9 項研究
- Boston, MA9 項研究
- Houston, TX8 項研究
- Atlanta, GA8 項研究
- Chicago, IL6 項研究
- Columbus, OH6 項研究
- Rochester, MN6 項研究
- New Haven, CT5 項研究
- Miami, FL5 項研究
- Ann Arbor, MI4 項研究
Seattle 的其他研究
- 非小細胞肺癌53 項研究
- 癌症(所有類型)49 項研究
- 前列腺癌42 項研究
- 急性髓系白血病40 項研究
- 乳癌39 項研究
- 轉移性癌症39 項研究
- 大腸直腸癌34 項研究
- 肺癌33 項研究
- 卵巢癌30 項研究
- 多發性骨髓瘤22 項研究
- 骨髓增生異常症候群21 項研究
- 急性淋巴母細胞性白血病21 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月5日。各研究自行設定資格標準;由研究團隊決定參與者資格。